Kezar Life Sciences Inc
KZR4.000USD
-0.050-1.23%
交易中 （美東）報價延遲15分鐘
29.22M總市值
虧損本益比TTM
關於 Kezar Life Sciences Inc 公司
Kezar Life Sciences, Inc. 是一家臨牀階段的生物製藥公司，專注於發現和開發小分子療法，以治療免疫介導疾病和癌症中未滿足的需求。該公司的主要候選產品 zetomipzomib 是一種同類首創的選擇性免疫蛋白酶體抑制劑，已完成健康志願者的 Ia 期測試和系統性紅斑狼瘡 (SLE) 患者（伴或不伴狼瘡性腎炎 (LN)）的 Ib/IIa 期臨牀試驗。其腫瘤候選產品 KZR-261 是一種小分子藥物，靶向 Sec61 轉運蛋白和蛋白質分泌途徑，正在進行一項開放標籤 I 期臨牀試驗，旨在評估安全性和耐受性、藥代動力學和藥效學，以及探索初步的抗腫瘤活性。這項研究分爲兩部分進行：對局部晚期或轉移性實體惡性腫瘤患者的劑量遞增，以及對選定腫瘤類型患者的劑量擴大。
公司簡介
公司代碼KZR
公司名稱Kezar Life Sciences Inc
上市日期Jun 21, 2018
CEODr. Christopher Kirk, Ph.D.
員工數量55
證券類型Ordinary Share
年結日Jun 21
公司地址4000 Shoreline Ct Ste 300
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編94080-2005
電話16508225600
網址https://kezarlifesciences.com/
公司代碼KZR
上市日期Jun 21, 2018
CEODr. Christopher Kirk, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. John Franklin Fowler
Mr. John Franklin Fowler
Director
Director
43.61K
--
Dr. Michael G. Kauffman, M.D., Ph.D.
Dr. Michael G. Kauffman, M.D., Ph.D.
Independent Director
Independent Director
6.37K
--
Mr. Marc L. Belsky
Mr. Marc L. Belsky
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
1.87K
-0.05%
Dr. Christopher Kirk, Ph.D.
Dr. Christopher Kirk, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Micki Klearman, M.D.
Dr. Micki Klearman, M.D.
Independent Director
Independent Director
--
--
Mr. Franklin M. Berger
Mr. Franklin M. Berger
Independent Director
Independent Director
--
--
Mr. Graham K. Cooper
Mr. Graham K. Cooper
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Courtney Wallace
Ms. Courtney Wallace
Independent Director
Independent Director
--
--
Mr. Mark Schiller
Mr. Mark Schiller
Chief Legal Officer
Chief Legal Officer
--
--
Dr. Elizabeth Garner, M.D.
Dr. Elizabeth Garner, M.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. John Franklin Fowler
Mr. John Franklin Fowler
Director
Director
43.61K
--
Dr. Michael G. Kauffman, M.D., Ph.D.
Dr. Michael G. Kauffman, M.D., Ph.D.
Independent Director
Independent Director
6.37K
--
Mr. Marc L. Belsky
Mr. Marc L. Belsky
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
1.87K
-0.05%
Dr. Christopher Kirk, Ph.D.
Dr. Christopher Kirk, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Micki Klearman, M.D.
Dr. Micki Klearman, M.D.
Independent Director
Independent Director
--
--
Mr. Franklin M. Berger
Mr. Franklin M. Berger
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月2日 週三
更新時間: 7月2日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Tang Capital Management, LLC
9.86%
Suvretta Capital Management, LLC
9.81%
Equal Talent Investments, Ltd.
8.44%
Avidity Partners Management LP
6.88%
BML Capital Management LLC
5.59%
Other
59.43%
持股股東
持股股東
佔比
Tang Capital Management, LLC
9.86%
Suvretta Capital Management, LLC
9.81%
Equal Talent Investments, Ltd.
8.44%
Avidity Partners Management LP
6.88%
BML Capital Management LLC
5.59%
Other
59.43%
股東類型
持股股東
佔比
Hedge Fund
36.09%
Investment Advisor
14.23%
Corporation
8.44%
Investment Advisor/Hedge Fund
5.63%
Private Equity
2.64%
Individual Investor
2.16%
Research Firm
0.47%
Other
30.35%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
206
5.15M
70.50%
-1.72M
2025Q1
258
5.21M
71.33%
-2.10M
2024Q4
278
5.09M
69.66%
-2.04M
2024Q3
292
4.99M
68.49%
-2.51M
2024Q2
303
5.03M
68.99%
-2.99M
2024Q1
309
5.63M
77.32%
-2.93M
2023Q4
309
6.08M
83.70%
-2.64M
2023Q3
309
6.63M
91.19%
-2.23M
2023Q2
309
7.09M
97.92%
-2.02M
2023Q1
307
7.44M
107.15%
-1.11M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Tang Capital Management, LLC
720.00K
9.86%
--
--
Mar 31, 2025
Suvretta Capital Management, LLC
716.76K
9.81%
--
--
Mar 31, 2025
Equal Talent Investments, Ltd.
616.50K
8.44%
--
--
Feb 28, 2025
Avidity Partners Management LP
502.60K
6.88%
--
--
Mar 31, 2025
BML Capital Management LLC
408.14K
5.59%
+39.54K
+10.73%
Mar 31, 2025
The Vanguard Group, Inc.
276.23K
3.78%
+2.12K
+0.77%
Mar 31, 2025
OrbiMed Advisors, LLC
192.70K
2.64%
--
--
Mar 31, 2025
Adar1 Capital Management LLC
147.40K
2.02%
--
--
Mar 31, 2025
Acadian Asset Management LLC
133.53K
1.83%
-12.14K
-8.33%
Mar 31, 2025
Peapod Lane Capital LLC
124.43K
1.7%
+433.00
+0.35%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Value ETF
0%
iShares Biotechnology ETF
0%
ProShares UltraPro Russell2000
0%
ALPS Medical Breakthroughs ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 3000 ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
查看更多
iShares Micro-Cap ETF
佔比0.01%
iShares Russell 2000 Value ETF
佔比0%
iShares Biotechnology ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
ALPS Medical Breakthroughs ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
iShares Russell 3000 ETF
佔比0%
Invesco Nasdaq Biotechnology ETF
佔比0%
ProShares Ultra Nasdaq Biotechnology
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Oct 28, 2024
Merger
10<1
Oct 28, 2024
Merger
10<1
Oct 28, 2024
Merger
10<1
Oct 28, 2024
Merger
10<1
公告日期
類型
比率
Oct 28, 2024
Merger
10<1
Oct 28, 2024
Merger
10<1
Oct 28, 2024
Merger
10<1
Oct 28, 2024
Merger
10<1
